Investment Analysts’ Recent Ratings Updates for 10x Genomics (TXG)

A number of firms have modified their ratings and price targets on shares of 10x Genomics (NASDAQ: TXG) recently:

• 8/12/2026 – 10x Genomics had its price target raised by Stephens from $50.00 to $65.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – 10x Genomics had its price target raised by Piper Sandler from $42.00 to $47.00. They now have a “neutral” rating on the stock.
• 8/10/2026 – 10x Genomics had its price target raised by Canaccord Genuity Group Inc. from $50.00 to $60.00. They now have a “buy” rating on the stock.
• 8/7/2026 – 10x Genomics had its price target raised by Morgan Stanley from $37.00 to $40.00. They now have an “equal weight” rating on the stock.
• 8/7/2026 – 10x Genomics was given a new $50.00 price target by Stifel Nicolaus.
• 8/7/2026 – 10x Genomics had its price target raised by Citigroup Inc. from $45.00 to $50.00. They now have a “neutral” rating on the stock.
• 7/17/2026 – 10x Genomics had its price target raised by Leerink Partners from $23.00 to $40.00. They now have a “market perform” rating on the stock.
• 7/15/2026 – 10x Genomics had its “hold” rating reaffirmed by TD Cowen.
• 7/14/2026 – 10x Genomics had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $50.00. They now have a “buy” rating on the stock.
• 7/9/2026 – 10x Genomics had its price target raised by Morgan Stanley from $22.00 to $37.00. They now have an “equal weight” rating on the stock.
• 7/8/2026 – 10x Genomics had its price target raised by Citigroup Inc. from $24.00 to $45.00. They now have a “neutral” rating on the stock.
• 7/1/2026 – 10x Genomics had its price target raised by Piper Sandler from $20.00 to $42.00. They now have a “neutral” rating on the stock.

Insider Transactions at 10x Genomics

In related news, CEO Serge Saxonov sold 30,000 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $34.44, for a total transaction of $1,033,200.00. Following the transaction, the chief executive officer owned 1,108,380 shares in the company, valued at $38,172,607.20. The trade was a 2.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John R. Stuelpnagel sold 20,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $57.75, for a total transaction of $1,155,000.00. Following the transaction, the director directly owned 348,436 shares in the company, valued at approximately $20,122,179. This represents a 5.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 55,723 shares of company stock valued at $2,374,941 in the last quarter. 8.84% of the stock is currently owned by company insiders.

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.